GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chugai Pharmaceutical Co Ltd (TSE:4519) » Definitions » Shiller PE Ratio

Chugai Pharmaceutical Co (TSE:4519) Shiller PE Ratio : 45.04 (As of May. 05, 2024)


View and export this data going back to 1956. Start your Free Trial

What is Chugai Pharmaceutical Co Shiller PE Ratio?

As of today (2024-05-05), Chugai Pharmaceutical Co's current share price is 円5094.00. Chugai Pharmaceutical Co's E10 for the quarter that ended in Mar. 2024 was 円113.09. Chugai Pharmaceutical Co's Shiller PE Ratio for today is 45.04.

The historical rank and industry rank for Chugai Pharmaceutical Co's Shiller PE Ratio or its related term are showing as below:

TSE:4519' s Shiller PE Ratio Range Over the Past 10 Years
Min: 33.92   Med: 54.62   Max: 132.28
Current: 45.04

During the past years, Chugai Pharmaceutical Co's highest Shiller PE Ratio was 132.28. The lowest was 33.92. And the median was 54.62.

TSE:4519's Shiller PE Ratio is ranked worse than
77.86% of 533 companies
in the Drug Manufacturers industry
Industry Median: 25.13 vs TSE:4519: 45.04

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Chugai Pharmaceutical Co's adjusted earnings per share data for the three months ended in Mar. 2024 was 円45.210. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is 円113.09 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Chugai Pharmaceutical Co Shiller PE Ratio Historical Data

The historical data trend for Chugai Pharmaceutical Co's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chugai Pharmaceutical Co Shiller PE Ratio Chart

Chugai Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 81.03 107.28 55.03 37.17 48.81

Chugai Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.52 41.09 44.38 48.81 50.97

Competitive Comparison of Chugai Pharmaceutical Co's Shiller PE Ratio

For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chugai Pharmaceutical Co's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Chugai Pharmaceutical Co's Shiller PE Ratio falls into.



Chugai Pharmaceutical Co Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Chugai Pharmaceutical Co's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=5094.00/113.09
=45.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chugai Pharmaceutical Co's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Chugai Pharmaceutical Co's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=45.21/107.2000*107.2000
=45.210

Current CPI (Mar. 2024) = 107.2000.

Chugai Pharmaceutical Co Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 6.180 98.000 6.760
201409 6.613 98.500 7.197
201412 6.863 97.900 7.515
201503 8.893 97.900 9.738
201506 9.483 98.400 10.331
201509 10.670 98.500 11.612
201512 8.213 98.100 8.975
201603 8.837 97.900 9.676
201606 10.390 98.100 11.354
201609 7.030 98.000 7.690
201612 6.400 98.400 6.972
201703 11.270 98.100 12.315
201706 10.717 98.500 11.664
201709 12.843 98.800 13.935
201712 9.440 99.400 10.181
201803 16.970 99.200 18.339
201806 12.647 99.200 13.667
201809 13.180 99.900 14.143
201812 13.470 99.700 14.483
201903 21.303 99.700 22.906
201906 20.810 99.800 22.353
201909 29.270 100.100 31.346
201912 24.420 100.500 26.048
202003 31.330 100.300 33.485
202006 30.850 99.900 33.104
202009 36.550 99.900 39.221
202012 31.790 99.300 34.319
202103 28.820 99.900 30.926
202106 42.990 99.500 46.317
202109 52.280 100.100 55.988
202112 60.080 100.100 64.341
202203 80.090 101.100 84.922
202206 43.990 101.800 46.323
202209 41.200 103.100 42.838
202212 62.280 104.100 64.135
202303 44.670 104.400 45.868
202306 50.560 105.200 51.521
202309 47.140 106.200 47.584
202312 55.430 106.800 55.638
202403 45.210 107.200 45.210

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Chugai Pharmaceutical Co  (TSE:4519) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Chugai Pharmaceutical Co Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Chugai Pharmaceutical Co's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Chugai Pharmaceutical Co (TSE:4519) Business Description

Traded in Other Exchanges
Address
1-1 Nihonbashi-Muromachi 2-Chome, Nihonbashi Mitsui Tower (Reception15F), Chuo-ku, Tokyo, JPN, 103-8324
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding Ltd, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and COVID-19.

Chugai Pharmaceutical Co (TSE:4519) Headlines

No Headlines